As a venture capital company, HBM BioVentures is invested globally in some 40 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The primary products of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The company focuses on unquoted emerging companies, with two-thirds are invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on the SIX Swiss Exchange (ticker: HBMN).

HBM Healthcare Investments

PTC Therapeutics raised $35000000 on 2004-01-07 in Series E

PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.

PTC Therapeutics, Inc.

Harmony Biosciences raised $270000000 on 2017-10-06 in Venture Round

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders. Its lead product includes WAKIX (pitolisant) for the treatment of pediatric patients suffering from narcolepsy. Harmony Biosciences Holdings, Inc. was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. The company was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings, Inc.

Neuron23 raised an undisclosed amount on 2020-10-19 in Series B

Neuron23, Inc. develops and manufactures medicines for genetic disorders through artificial intelligence technology and genetics. It offers medicines for neurological diseases and immunological disorders. The company was incorporated in 2018 and is based in South San Francisco, California with an additional office in Munich, Germany.

Neuron23

Shape Memory Medical raised an undisclosed amount on 2021-03-25 in Convertible Note

Shape Memory Therapeutics, Inc., a medical device company, focuses on the commercialization of medical devices based on shape memory polymer materials for minimally invasive (endovascular) applications. The company was founded in 2009 and is based in College Station, Texas.

Shape Memory Therapeutics, Inc.

MiCardia Corporation raised $5000000 on 2008-07-11 in Venture Round

MiCardia is a privately held medical device company currently preparing for the commercialization of its first series of products, enCor™, in the European Union. enCor is a unique device that surgically treats mitral valve regurgitation. enCor utilizes the company's patented technology, Dynaplasty™, to provide a "second chance" to the patient who develops recurrent regurgitation. enCor can be activated to physiologically adjust the mitral valve leaflets to resolve regurgitation, minimally invasively, weeks to years later, without the need for the risk and cost of redo surgery.

MiCardia Corporation

connectRN raised an undisclosed amount on 2021-04-06 in Series E

ConnectRN, Inc. operates an online platform for hospitals and healthcare institutions to communicate with available nurses. The company’s platform provides various tools to connect healthcare providers to qualified and available staff via an alert system that is sent to their mobile devices. Its nurse management Web dashboard streamlines communication between nurses and nurse managers to ensure open shifts are filled. ConnectRN, Inc. was incorporated in 2014 and is based in Newton, Massachusetts.

ConnectRN, Inc.

Surface Logix raised $42000000 on 2005-10-28 in Venture Round

Surface Logix is a drug development company which uses its expertise in biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic (PK) and pharmacodynamic (PD) properties compared with class leaders.

Surface Logix

1mg raised $70000000 on 2019-06-28 in Series D

1mg is a digital consumer healthcare platform that makes healthcare accessible, understandable, and affordable. It allows users to find information about medicines prescribed by doctors and also buy it. Users can find drugs by ailments, class, companies, and brands. Its doctor platform aims to transform how to find the right healthcare professional for a consumers' needs. Its diagnostics service brings transparency and price-effectiveness to lab tests.

The company empowers Indian consumers and caregivers to select the most appropriate healthcare service at the best possible price. 1mg was launched on 2015 and its operations are headquartered in Gurugram, India.

Medd

CardiaLen raised an undisclosed amount on 2021-06-24 in Convertible Note

Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Cardialen, Inc.

Dren Bio raised $65000000 on 2022-06-14 in Series B

Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.

Dren Bio

POLYNEURON raised $15375069 on 2020-09-16 in Series A

Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patients with immune disorders in a safe and effective manner.

Polyneuron Pharmaceuticals AG

Karius raised $165000000 on 2020-02-24 in Series B

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions.  By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer  a major threat to human health.  The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.

Karius, Inc.

Nuance Biotech raised $2000000 on 2019-03-22 in Series C

NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.

Nuance Biotech

Sublimity Therapeutics raised an undisclosed amount on 2020-08-17 in Series B

Sublimity Therapeutics (formerly Sigmoid Pharma), is a specialty pharma company with offices in Dublin, Ireland, and Solana Beach, California. Sublimity’s goal is to identify and create meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Sublimity’s priority focus is on its lead product, STI-0529, for treatment of moderate to severe ulcerative colitis.

Sublimity Therapeutics

Vivacta raised $4500000 on 2009-06-30 in Venture Round

Vivacta Limited, a Sittingbourne, UK-based medical diagnostics company that develops an innovative platform for point of care testing.

Vivactaâ€™s innovative piezofilm technology platform enables the advancement of new nearâ€patient diagnostic products. The company has successfully developed a test for thyroid stimulating hormone (TSH), and is working on a multiple analyte cardiovascular diagnostic test for use in the emergency room and acute
care settings, where there is a need for rapid diagnosis of possible heart attack and related timeâ€critical medical conditions.

Vivacta

Acrivon Therapeutics raised $100000000 on 2021-11-11 in Series B

Acrivon Therapeutics is a biotech company specializing in drug development through early clinical treatment success.

Acrivon Therapeutics

connectRN raised $76000000 on 2021-12-08 in Venture Round

Shape Memory Medical raised an undisclosed amount on 2020-05-04 in Series B

SK biopharmaceuticals raised $180000000 on 2021-11-26 in Series A

SK biopharmaceuticals aims to become a top tier specialty pharmaceutical company with global new drugs & innovative pipeline in CNS / metabolic disorders and to provide world class specialized pharmaceutical manufacturing services.

SK biopharmaceuticals

Galileo Genomics raised $16500000 on 2001-10-10 in Venture Round

Galileo genomics is a Montreal-based private genetics company that conducts research in Quebecers of French descent using cutting-edge technologies, to identify genes that cause disease, thus providing validated targets for creation of innovative and more effective therapies and diagnostics. The Quebec founder population is the largest such population worldwide, which facilitates rapid patient recruiting. Because of the relatively late founding of the population in the 17th century, the relatively small number of founders, rapid early population growth, minimal intermarriage with other groups, and loss of some family lines while others expanded dramatically, the population is among the most homogeneous and has among the highest genetic sharing of all major founder populations.

Galileo Genomics

C Ray Therapeutics raised an undisclosed amount on 2021-07-30 in Series A

C Ray Therapeutics develops healthcare advancements through nuclear medicine. It was founded in 2020.

C Ray Therapeutics

MTM Laboratories raised $57118419 on 2009-10-05 in Series C

mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer.

These kits are based on mtm's proprietary E6H4(TM) antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results.

MTM Laboratories

Triage Medical raised $10000000 on 2003-08-20 in Series B

Triage Medical Inc., an Irvine, Calif.-based developer orthopedic trauma devices.

Triage Medical

Monte Rosa Therapeutics raised $95000000 on 2021-03-12 in Series C

Monte Rosa Therapeutics is a biotechnology company that develops cancer therapeutics that modulate protein degradation pathways. It is headquartered in Basel, Switzerland.

Monte Rosa Therapeutics

Karius raised an undisclosed amount on 2021-01-20 in Series B

Vascular Dynamics raised $394000 on 2019-02-28 in Convertible Note

Vascular Dynamics, Inc. develops and commercializes a catheter-delivered implant for the treatment of drug-resistant hypertension. It offers MobiusHD, an hypertension treatment amplifying the natural baroreceptor response in the carotid sinus with a minimally invasive procedure to stimulate vasodilation, reduce heart rate, modulate kidney response, and decrease blood pressure. The company was founded in 2008 and is based in Irvine, California.

Vascular Dynamics

Mineralys Therapeutics raised $118000000 on 2022-06-08 in Series B

Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company founded by Catalys Pacific committed to developing best-in-class, novel therapy for the treatment of hypertension. The Company is driven to bring a targeted approach to the management of hypertension via the development of MLS-101. MLS-101, licensed from Mitsubishi Tanabe Pharma Corporation, is a highly selective and potent aldosterone synthase inhibitor that is being investigated for the treatment of hypertension.

Mineralys Therapeutics

Galera Therapeutics raised $70000000 on 2018-09-19 in Series C

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company’s lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer. It is also involved in developing GC4711, which is in Phase I/II clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Galera Therapeutics, Inc.

Vivoryon Therapeutics raised $19409862 on 2012-01-04 in Venture Round

Vivoryon Therapeutics is a Germany based biopharmaceutical company engaged in the activities of research and development, preclinical and clinical trials. It is focused on the development of therapeutic products for the treatment of Alzheimer's disease and cancer. The company's pipeline products includes PQ912, PQ1565 and PQ-family.

Probiodrug

Aculys Pharma raised $22652622 on 2022-03-28 in Series B

Accuris Pharma is a pharmaceutical company that aims to develop innovative and superior medical methods and deliver them to patients.

Aculys Pharma

Adrenomed raised an undisclosed amount on 2021-03-23 in Convertible Note

Adrenomed AG, a biopharmaceutical company, engages in the development of monoclonal antibody therapies for the treatment of sepsis. The company develops Adrecizumab, a humanized monoclonal antibody drug candidate against Adrenomedullin, a vasoactive peptide hormone released by vascular endothelial cells. Adrenomed AG was founded in 2009 and is based in Hennigsdorf, Germany.

Adrenomed AG

Farmalisto raised $2000000 on 2019-08-27 in Convertible Note

Farmalisto is an online retailer that sells a range of products and services to its clients.

The platform’s range of products include haircare, dampeners, solar protection, healing, moisturizing, anti-aging, toothbrushes, toothpastes, mouth rinses, dental silks, dentures, protection, cereals, baby hygiene, baby milks, and diapers.

Farmalisto was launched in 2013 by Jose Mora Hernandez, Stefan Krautwald, and Matthias Fehr and is based in Bogota and Mexico City.

Websites:

https://www.farmalisto.com.mx
https://www.farmalisto.com.co

Farmalisto

Neurelis raised $114000000 on 2021-03-10 in Series D

Neurelis is a specialty pharmaceutical company, licenses, develops, and commercializes product candidates for epilepsy and the broader central nervous system (CNS) market. It provides a differentiated approach to target unmet medical needs. Their application of novel technologies is designed to enhance  the therapeutic benefit and patient care.

The company was incorporated in 2007 and is based in Encinitas, California.

Neurelis, Inc.

Neuron23 raised $80000000 on 2020-12-16 in Series B

Nereus Pharmaceuticals raised $42600000 on 2005-10-19 in Series D

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Nereus Pharmaceuticals

Y-mAbs Therapeutics raised $50000000 on 2017-10-24 in Private Equity Round

YmAbs is a clinical stage biopharmaceutical company that discovers and develops innovative treatments for cancer patients through immunotherapies. YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies. To further improve its bispecific antibodies, the company collaborates on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. 

YmAbs' treatments claims to potentially reduce longer-term toxicities associated with current chemotherapeutics and provide the potential for curative therapy even for patients with widespread disease. YmAbs’ goal is to drive multiple product candidates in select solid tumor cancers to FDA approval.

Y-mAbs Therapeutics

SpringWorks Therapeutics raised $125000000 on 2019-04-01 in Series B

SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others.

The company was founded in 2017 and headquartered in Connecticut, United States.

SpringWorks Therapeutics

Cathay Biotech raised $9963323 on 2019-06-14 in Series B

Cathay Industrial Biotech, Ltd produces and sells green materials from renewable sources as an alternative to chemically manufactured products worldwide. It provides long-chain dibasic acids, bio-based pentamethylene diamine, and bio-based green nylons. The company is based in Shanghai, China.

Cathay Industrial Biotech

ARMO BioSciences raised $50000000 on 2016-02-10 in Series C

ARMO Biosciences is a biotechnology company that develops immune modulatory biologic therapeutics. The company is based in Redwood City, California.

ARMO BioSciences, Inc.

Adrenomed raised an undisclosed amount on 2020-06-17 in Convertible Note

Ignis Therapeutics raised $180000000 on 2021-11-11 in Series A

Ignis Therapeutics

Karius raised an undisclosed amount on 2022-03-07 in Series B

BaseHealth raised $8500000 on 2017-10-18 in Series C

BaseHealth is a predictive health platform that is evidence-based and data-driven without reliance on retrospective claims and ICD data. The company’s proprietary platform leverages machine learning to sift through millions of medical journals and patient records curated by scientists and physicians to offer healthcare providers the ability to identify patients with underlying risks for 43 chronic diseases and prevent costly treatments before they’re needed. 

It was founded in 2008 and headquartered in Sunnyvale, California.

BaseHealth, Inc.

Novellus raised $57000000 on 2020-09-23 in Series C

Novellus is a biotechnology company working to develop engineered cellular medicines. The company uses its non-immunogenic mRNA molecules to reprogram and gene-edit cells safely, and with high efficiency. They engineer precision medicines for patient segments and select from its technology toolbox for in vivo, ex vivo, allogeneic and autologous delivery.

Novellus platform enables the high-level expression of gene-editing and cell-reprogramming proteins for high-specificity gene repair and both autologous and allogeneic cell therapies. The company is advancing its lead program, a breakthrough therapy for a rare dermatologic disease, through pre-clinical studies.

Novellus was founded in 2015 and is headquartered in Cambridge, Massachusetts, United States.

Novellus

MTM Laboratories raised $28000000 on 2006-10-10 in Series C

Homology Medicines raised $83500000 on 2017-08-01 in Series B

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company’s various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Homology Medicines, Inc.

Pelikan Technologies raised $69000000 on 2007-12-06 in Series F

Pelikan Technologies is dedicated to the development of innovative hand-held diagnostic and monitoring devices capable of significantly improving the screening and management of a variety of medical conditions.

Pelikan Technologies

Everlife raised an undisclosed amount on 2020-11-23 in Series A

Everlife Asia is a buy-and-build platform aimed to provide complete solutions for the healthcare and research industries.

Everlife Holdings Pte Ltd

Harmony Biosciences raised $50000000 on 2019-08-26 in Series C

Monte Rosa Therapeutics raised $96000000 on 2020-09-24 in Series B

Thommen Medical raised $10830757 on 2003-11-26 in Series C

Thommen Medical develops, produces and sells dental implants under the brand name SPI (Swiss Precision Implant) as well as biomaterial solutions for bone and tissue regeneration. Thommen Medical Implants are designed to be precise and easy to use, thanks to collaboration with leading scientific and dental clinicians.

Thommen Medical

Mineralys Therapeutics raised $40000000 on 2021-04-06 in Series A

Fore Biotherapeutics raised an undisclosed amount on 2021-09-15 in Series C

Novellusdx develops tumor specific driver mutations. It focuses on testing targeted therapy drugs on emulated tumors and quantifying their therapeutic effect, monitoring the oncogenic activity of the patient's relevant genes and proteins, and monitoring the oncogenic activity before and after drug administration. 

Novellusdx develops assays that detect disregulated translocation of mutated signaling proteins to the nucleus; and measures the impact of a drug or drug candidate on a specific tumor, specifically in terms of its ability to inhibit the up-regulated signaling protein translocation to the nucleus. Haim Gil-ad and Yoram Altschuler founded it on May 1, 2011, with its headquarters in Jerusalem in Israel.

Novellusdx Ltd.

IO Biotech raised an undisclosed amount on 2021-10-07 in Series C

IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

IO Biotech

Antiva Biosciences raised $31000000 on 2021-11-02 in Series D

Antiva Biosciences is a biopharmaceutical company developing novel, localized therapeutics for the treatment of diseases caused by HPV infection. The company was founded as Hera Therapeutics in 2012 by Dr. Karl Hostetler at The University of California San Diego. They are now Antiva Biosciences which is headquartered in South San Francisco.

Antiva Biosciences, Inc.

Neuron23 raised an undisclosed amount on 2021-11-09 in Series C

1000Farmacie raised $15000000 on 2022-02-07 in Series A

1000Farmacie SRL operates an online platform of retail pharmacies. It sells products authorized for online sale and with CE guarantee mark. It also sells products, such as cosmetics, food supplements, and pet care products. The company is based in Naples, Italy.

1000Farmacie SRL

Autonomic Technologies raised $43200000 on 2015-06-25 in Series D

Autonomic Technologies, Inc. is a medical device company that focuses on the development and commercialization of therapies for the treatment of autonomic disorders, particularly severe headache. It develops ATI Neurostimulation System, a device that delivers low-level energy directly to the area of the SPG for the treatment of chronic cluster headache. The company was founded in 2007 and is based in Mountain View, California with additional offices in Germany and Switzerland.

Autonomic Technologies

Sphingotec GmbH raised an undisclosed amount on 2021-05-06 in Convertible Note

Sphingotec GmbH develops biomarkers for diagnosis, prediction, and monitoring of acute medical conditions, such as acute heart failure, acute kidney injury, and circulatory shock. The company was founded in 2002 and is based in Brandenburg, Germany.

Sphingotec GmbH

Mineralys Therapeutics raised an undisclosed amount on 2022-01-18 in Series A

Connect Biopharmaceuticals raised $115000000 on 2020-08-24 in Series C

Suzhou Connect Biopharmaceuticals, Ltd., a clinical-stage company, discovers and develops novel medicines for the treatment of autoimmune diseases and inflammation. Its products in pipeline includes CBP-307, an orally-active, second-generation S1P1 agonist for the treatment of a range of autoimmune diseases, including inflammatory bowel disease, graft-versus-host disease, psoriasis, and multiple sclerosis; CBP-174 for allergic rhinitis and atopic dermatitis; and CBP-201, a novel monoclonal antibody for the treatment of atopic dermatitis, asthma, and other types of allergic inflammation. The company is headquartered in Taicang, China with operations in Melbourne and San Diego.

Connect Biopharmaceuticals

Odyssey Therapeutics raised $218000000 on 2021-12-07 in Series A

Odyssey Therapeutics

Celladon raised $39500000 on 2015-11-18 in Post-IPO Equity

Celladon Corporation, a biotechnology company, develops and manufactures molecular therapies for the treatment of heart failure. Its products include SERCA2a, an enzyme that regulates calcium cycling and contractility in heart muscle cells; and MYDICAR, an enzyme replacement therapy for heart failure. Celladon was founded in 2000 and is based in La Jolla, California.

Celladon

Dren Bio raised an undisclosed amount on 2021-10-20 in Series A

Fog Pharmaceuticals raised $23271035 on 2021-01-04 in Venture Round

FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.

FogPharma is laser-focused and unstoppable in its mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.

Fog Pharmaceuticals, Inc.

Galecto raised $64000000 on 2020-09-25 in Series D

Galecto, Inc. develops small molecules for the treatment of severe diseases, including fibrosis and cancer. The company, founded in 2011, builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.

Galecto Biotech

ARMO BioSciences raised $67000000 on 2017-08-29 in Series C

Odyssey Therapeutics raised $10000000 on 2021-10-22 in Series A

Odyssey Therapeutics is building a machine learning-based platform to develop novel therapeutics focusing on cancer and autoimmune diseases.

BioAtla raised $75000000 on 2021-09-29 in Post-IPO Equity

BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.

BioAtla LLC

4TEEN4 Pharmaceuticals raised $23048989 on 2018-10-07 in Venture Round

ChemoCentryx raised $17700000 on 2006-08-24 in Series C

ChemoCentryx focuses on discovery, development and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. 
Their small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

ChemoCentryx, Inc.

Swixx Biopharma raised an undisclosed amount on 2021-12-08 in Venture Round

Swixx Biopharma fully represents biopharma companies in the CEE. It is designed to fully replace biopharma, OTC, and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit.

The company was founded in 2014 and is registered in Baar, Switzerland. It has 100%-owned affiliates in Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Greece, Hungary, Kosovo, Latvia, Lithuania, North Macedonia, Montenegro, Poland, Romania, Russia, Serbia, Slovakia, and Slovenia.

Swixx Biopharma

Ellipse Technologies raised $17600000 on 2011-08-02 in Series C

Ellipse Technologies is focused on developing its implantable remote control technology platforms to include innovative treatments for a broad spectrum of spinal and orthopedic deformity applications, orthopedic trauma and fracture management.

The initial products restore proper anatomic position and alignment of the spine and long-bones. MAGECâ„¢ MAGnetic Expansion Control System utilizes a novel motion-preserving, minimally-invasive technology that, through communication with an external magnetic field, can be non-invasively adjusted in an outpatient setting via remote control by the physician to correct spinal deformities. PRECICE System uses non-invasive adjustable intramedullary rods or bone plates to treat long-bone abnormalities, often the result of acute or chronic fractures.

Ellipse is a privately-held medical device company located in California.

Ellipse Technologies

ITeos Therapeutics raised $125000000 on 2020-04-01 in Series B

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Iteos Therapeutics S.A.

Adrenomed raised an undisclosed amount on 2022-01-04 in Convertible Note

Vascular Dynamics raised $20000000 on 2022-07-12 in Venture Round

Sloning BioTechnology raised $6789474 on 2007-11-01 in Series E

Sloning BioTechnology has developed a unique and patented technology platform to build DNA molecules with exceptional features regarding sequence limitations, reliability and production cost on an industrial scale robotic system the Slonomics technology platform.

Sloning BioTechnology

Arrakis Therapeutics raised $75000000 on 2019-04-18 in Series B

Arrakis Therapeutics is a developer of a drug discovery platform intended to target RNA. The company's platform integrates leading-edge RNA bioinformatic and structural tools to produce a pipeline of rSMs to treat a range of disease including neurology, oncology and rare genetic diseases, enabling physicians to offer enhanced care.

Arrakis Therapeutics

1mg raised $40062839 on 2022-09-06 in Venture Round

Broncus Technologies raised $15800000 on 2004-05-25 in Series E